Ivermectin and Gynecologic Cancer: What are the data?

•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to ef...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology reports Vol. 60; p. 101803
Main Authors: Mujumdar, Vaidehi, Huang, Marilyn, Smith, Lindsey Chippendale, Musa, Fernanda
Format: Journal Article
Language:English
Published: Elsevier Inc 01.08.2025
Elsevier
Subjects:
Anti-helminthic
COVID-19
Gynecologic cancers
Ivermectin
Wonder drug
COVID-19
Gynecologic cancers
Wonder drug
Anti-helminthic
Ivermectin
ISSN:2352-5789, 2352-5789
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.•We have not assessed ivermectin’s safety and efficacy in gynecologic cancers.•We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.
ISSN:2352-5789
2352-5789
DOI:10.1016/j.gore.2025.101803